SCHEMBL24737388

SCHEMBL24737388

Cc1cc(C2CC2)cn2cc(CN3C(=O)c4ccccc4C3=O)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
RECQL P46063 1/20 0.46
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 2/20 0.39
TGFBR1 P36897 1/20 0.39
ACHE P22303 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PDE8B O95263 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HPGD P15428 2/20 0.36
PABPC1 P11940 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24738949 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL27030193 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL29879647 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL24737332 0.86 TYR (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL24737369 0.86 TYR (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL29830298 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL24738099 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL29879026 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL24737665 0.86 MAPT (0.41) MAPTRECQLALDH1A1MEN1KMT2A
SCHEMBL24738187 0.85 MAPT (0.40) MAPTRECQLALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 MAPT 3787/4885RECQL 2762/4885ALDH1A1 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.